Accustem Sciences Inc. (ACUT) Financial Statements (2026 and earlier)

Company Profile

Business Address 5 PENN PLAZA, 19TH FLOOR
NEW YORK, NY 10001
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,9295,04621,481733,978
Cash and cash equivalent13,9295,04621,481733,978
Prepaid expense35,51745,387108,368168,430
Other current assets    29,603
Total current assets:49,44650,433129,849932,011
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization  4184,0487,678
Other undisclosed noncurrent assets1,500,000   
Total noncurrent assets:1,500,0004184,0487,678
TOTAL ASSETS:1,549,44650,851133,897939,689
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities705,687968,668734,812830,459
Accounts payable703,812804,615578,378311,834
Accrued liabilities1,875164,053156,434518,625
Debt 22,54625,14855,679106,551
Other liabilities4,222,8382,370,2591,454,986 
Due to related parties✕✕✕✕142,229
Total current liabilities:4,951,0713,364,0752,245,4771,079,239
Noncurrent Liabilities
Total liabilities:4,951,0713,364,0752,245,4771,079,239
Equity
Equity, attributable to parent(3,401,625)(3,313,224)(2,111,580)(139,550)
Common stock16,07212,10011,34611,346
Additional paid in capital6,365,4464,701,7234,399,0194,320,385
Accumulated deficit(9,783,143)(8,027,047)(6,521,945)(4,471,281)
Total equity:(3,401,625)(3,313,224)(2,111,580)(139,550)
TOTAL LIABILITIES AND EQUITY:1,549,44650,851133,897939,689

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Gross profit:    (35,668)
Operating expenses(1,756,096)(1,505,102)(2,050,664)(3,746,419)
Other undisclosed operating income    35,668
Operating loss:(1,756,096)(1,505,102)(2,050,664)(3,746,419)
Net loss available to common stockholders, diluted:(1,756,096)(1,505,102)(2,050,664)(3,746,419)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Net loss:(1,756,096)(1,505,102)(2,050,664)(3,746,419)
Comprehensive loss, net of tax, attributable to parent:(1,756,096)(1,505,102)(2,050,664)(3,746,419)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: